If they can get the pps to $1+ by then, they will deserve those performance shares, despite the major stuff up in the 1st US clinical trial (it did allow me to buy a lot of shares cheap.....), if they can't achieve that pps, they don't deserve it.
The dawn of Revenue for RAP, page-21
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
